EZH2 and neoplasm: On one hand, epigenetic modifiers such as DNMT inhibitors, HDAC inhibitors, EZH2 inhibitors and FXR inhibitors have shown potential effects in disrupting the EMT process, influencing the tumor microenvironment, especially regulating immune cell function and chemokine release, and inhibiting tumor progression.